Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C10H14F2N2O2 |
Molecular Weight | 232.2272 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@H](N1C[C@@H](CC1=O)C=C(F)F)C(N)=O
InChI
InChIKey=ANWPENAPCIFDSZ-RQJHMYQMSA-N
InChI=1S/C10H14F2N2O2/c1-2-7(10(13)16)14-5-6(3-8(11)12)4-9(14)15/h3,6-7H,2,4-5H2,1H3,(H2,13,16)/t6-,7+/m1/s1
Seletracetam, a pyrrolidone derivative is a new drug in epilepsy development. Seletracetam has high binding affinity to the synaptic vesicle 2A (SV2A) protein. In addition, was discovered, that the drug bound to N-type calcium channels and inhibited high-voltage-activated Ca2+ currents and intracellular Ca2+ increase. Seletracetam participated in Phase III clinical trials; however, all these studies for the treatment of epilepsy were terminated. Moreover, it is unknown whether planned phase IIb/III trials will begin.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Antiepileptic drug discovery: lessons from the past and future challenges. | 2005 |
|
Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). | 2007 Jan |
|
Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy. | 2009 Jul 1 |
|
Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. | 2010 Feb 12 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00152503
Ucb 44212 (Seletracetam) Used at Doses of 10, 20, 40, and 80 mg b.i.d. (Total Daily Doses of 20 - 160 mg) Administration (Oral Capsules) in Adult Subjects (18 - 65 Years)
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C264
Created by
admin on Fri Dec 15 15:30:35 GMT 2023 , Edited by admin on Fri Dec 15 15:30:35 GMT 2023
|
||
|
NCI_THESAURUS |
C1509
Created by
admin on Fri Dec 15 15:30:35 GMT 2023 , Edited by admin on Fri Dec 15 15:30:35 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
QQ-110
Created by
admin on Fri Dec 15 15:30:35 GMT 2023 , Edited by admin on Fri Dec 15 15:30:35 GMT 2023
|
PRIMARY | |||
|
CHEMBL2104983
Created by
admin on Fri Dec 15 15:30:35 GMT 2023 , Edited by admin on Fri Dec 15 15:30:35 GMT 2023
|
PRIMARY | |||
|
357336-74-4
Created by
admin on Fri Dec 15 15:30:35 GMT 2023 , Edited by admin on Fri Dec 15 15:30:35 GMT 2023
|
PRIMARY | |||
|
SELETRACETAM
Created by
admin on Fri Dec 15 15:30:35 GMT 2023 , Edited by admin on Fri Dec 15 15:30:35 GMT 2023
|
PRIMARY | |||
|
300000034404
Created by
admin on Fri Dec 15 15:30:35 GMT 2023 , Edited by admin on Fri Dec 15 15:30:35 GMT 2023
|
PRIMARY | |||
|
9942725
Created by
admin on Fri Dec 15 15:30:35 GMT 2023 , Edited by admin on Fri Dec 15 15:30:35 GMT 2023
|
PRIMARY | |||
|
RFR2CH3QZK
Created by
admin on Fri Dec 15 15:30:35 GMT 2023 , Edited by admin on Fri Dec 15 15:30:35 GMT 2023
|
PRIMARY | |||
|
DTXSID30905079
Created by
admin on Fri Dec 15 15:30:35 GMT 2023 , Edited by admin on Fri Dec 15 15:30:35 GMT 2023
|
PRIMARY | |||
|
8641
Created by
admin on Fri Dec 15 15:30:35 GMT 2023 , Edited by admin on Fri Dec 15 15:30:35 GMT 2023
|
PRIMARY | |||
|
C66534
Created by
admin on Fri Dec 15 15:30:35 GMT 2023 , Edited by admin on Fri Dec 15 15:30:35 GMT 2023
|
PRIMARY | |||
|
DB05885
Created by
admin on Fri Dec 15 15:30:35 GMT 2023 , Edited by admin on Fri Dec 15 15:30:35 GMT 2023
|
PRIMARY |
ACTIVE MOIETY